Cargando…

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Shibo, Hillyer, Christopher, Du, Lanying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129017/ https://www.ncbi.nlm.nih.gov/pubmed/32249063 http://dx.doi.org/10.1016/j.it.2020.03.007

Ejemplares similares

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355–359; 2020)
por: Jiang, Shibo, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
por: Jiang, Shibo, et al.
Publicado: (2020)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses
por: Zeng, Lei-Ping, et al.
Publicado: (2017)

Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
por: Ma, Cuiqing, et al.
Publicado: (2020)

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2013)

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
por: He, Yuxian, et al.
Publicado: (2006)

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses
por: Bajpai, Prashant, et al.
Publicado: (2022)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
por: Zhou, Guangyu, et al.
Publicado: (2020)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
por: Wang, Gang, et al.
Publicado: (2022)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC
por: Jiang, Shibo, et al.
Publicado: (2013)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022)

Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody
por: Ying, Tianlei, et al.
Publicado: (2015)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
por: Guan, Xiaoqing, et al.
Publicado: (2023)

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2
por: Konwarh, Rocktotpal
Publicado: (2020)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

Potently neutralizing and protective human antibodies against SARS-CoV-2
por: Zost, Seth J., et al.
Publicado: (2020)

Perspectives on the development of neutralizing antibodies against SARS-CoV-2
por: Ho, Mitchell
Publicado: (2020)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
por: Du, Lanying, et al.
Publicado: (2009)

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
por: Qu, Yuanyuan, et al.
Publicado: (2021)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ccj94rddjjga79qqa0sqhcrmm4